How to Get Semaglutide from Compounding Pharmacy: A Comprehensive Guide

Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The process has three fixed steps and no shortcuts: a clinical evaluation by a licensed prescriber, an individual prescription written for you, and dispensing by a state-licensed pharmacy. The FDA’s guidance is stated plainly — patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy. Before any of that, though, there is a threshold question the agency is equally clear about: compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.

Step Zero: Establish Whether an Approved Product Fits

This step is skipped constantly and it is the one the FDA emphasises. The agency describes a compounded drug as potentially appropriate if a patient’s medical need cannot be met by an FDA-approved drug, or if the FDA-approved drug is not commercially available.

The approved semaglutide products cover substantial ground: Ozempic injection for three type 2 diabetes indications, Rybelsus and Ozempic tablets for glycemic control and cardiovascular risk reduction, and Wegovy injection and tablets for cardiovascular risk reduction, weight reduction and, for the injection, noncirrhotic MASH.

Whether one of those fits your situation is a clinical question for a prescriber. It is also a coverage question, since an approved product may be covered where a compounded preparation never is.

Step One: The Clinical Evaluation

Expect the same screening a clinic visit would involve. Every semaglutide label carries a boxed warning on rodent thyroid C-cell tumors and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, so personal and family history questions come first.

Beyond that, history of pancreatitis, gallbladder disease, severe gastrointestinal disease, diabetic retinopathy, kidney impairment and pregnancy planning all shape the assessment. The labeling directs discontinuation in women at least two months before a planned pregnancy because of semaglutide’s long washout period.

Your current medication list matters as well, since delayed gastric emptying can affect absorption of oral drugs and the labels differ on how strongly they address it.

Step Two: The Prescription Must Be Individual

Section 503A conditions compounding on a valid prescription order for an identified individual patient, generated within an established relationship between the prescriber and the patient, or between the prescriber and the pharmacist. There is no lawful route that omits this.

The FDA lists absence of screening and a prescription by a licensed doctor before medicine is provided among its consumer red flags for this market, alongside the absence of a licensed doctor available to answer questions after you receive the medication.

Step Three: The Dispensing Pharmacy

Federal law addresses compounding by a licensed pharmacist in a state-licensed pharmacy, and the FDA states that state boards of pharmacy generally hold primary responsibility for day-to-day oversight of such pharmacies when they are not registered as outsourcing facilities, with the FDA conducting surveillance and for-cause inspections.

Ingredient standards are set in statute. Bulk drug substances must comply with an applicable United States Pharmacopeia or National Formulary monograph where one exists, be manufactured by an FDA-registered establishment, and be accompanied by valid certificates of analysis.

Quality-system requirements differ by setting: current good manufacturing practice requirements apply to outsourcing facilities but not to drugs compounded under section 503A in a state-licensed pharmacy. Federal provisions on insanitary conditions apply regardless.

What to Verify Before You Accept a Shipment

Injectable GLP-1 drugs require refrigeration as indicated in their package inserts, and the FDA recommends that patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, because this can affect the drug’s quality. The agency has received complaints about compounded products arriving warm or with inadequate ice packs.

The agency has also documented fraudulent compounded semaglutide and tirzepatide carrying false label information, in some cases naming pharmacies that do not exist and in others naming licensed pharmacies that did not compound the product. Verifying the dispensing pharmacy independently is reasonable diligence.

What to Keep in Mind Once You Start

The FDA has received multiple adverse event reports, some requiring hospitalisation, that may relate to dosing errors with compounded injectable semaglutide, arising from patients measuring and self-administering incorrect doses and from professionals miscalculating doses. It advises patients to talk with their health care provider or compounder about how to measure and administer the intended dose.

That conversation belongs with the prescriber and the pharmacy, not with an article or a forum. Keep a clinician reachable, and treat any question about measurement, storage or schedule as a question for them.

Why the Landscape Changed in 2025

Compounded semaglutide and tirzepatide became widely available during a period when the approved products were in shortage, because federal law permits compounders to prepare versions of a drug on the FDA’s shortage list under certain conditions. Those shortages were resolved, with the agency’s enforcement discretion periods for tirzepatide ending in February and March 2025 and for semaglutide in April and May 2025.

That matters for how you evaluate a source today. Section 503A prohibits compounding regularly or in inordinate amounts any drug product that is essentially a copy of a commercially available drug product, and the shortage-based rationale that applied during the shortage period no longer does.

It is a reasonable question to put to any pharmacy or platform: on what basis is a compounded preparation appropriate for me specifically, rather than an approved product? The FDA frames the same test as whether a patient’s medical need can be met by an FDA-approved drug.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What is the first step to getting compounded semaglutide?

A clinical evaluation by a licensed prescriber, who determines whether an FDA-approved product fits your situation first. The FDA states that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, or where the approved drug is not commercially available. Only then does the prescription and pharmacy step follow.

Can a compounding pharmacy dispense without an individual prescription?

No. Section 503A conditions compounding on a valid prescription order for an identified individual patient, generated within an established relationship between prescriber and patient, or between prescriber and pharmacist. The FDA lists absence of screening and a prescription by a licensed doctor before medicine is provided among its published consumer red flags for this market.

What ingredient standards apply to the pharmacy?

Bulk drug substances used in compounding must comply with the standards of an applicable United States Pharmacopeia or National Formulary monograph where one exists and the USP chapter on pharmacy compounding, be manufactured by an establishment registered with the FDA, and be accompanied by valid certificates of analysis for each bulk drug substance.

Are compounding pharmacies held to manufacturing standards?

It depends on the setting. The FDA states that drugs compounded in outsourcing facilities are subject to current good manufacturing practice requirements, while drugs compounded by a licensed pharmacist in a state-licensed pharmacy in accordance with section 503A are not. Federal provisions regarding insanitary conditions apply regardless of where compounding occurs.

What should I do if my medication arrives warm?

Do not use it. The FDA recommends that patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, since this can affect the drug’s quality, and it has received complaints about compounded GLP-1 products arriving warm or with inadequate ice packs. Contact the dispensing pharmacy and your prescriber.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.